Symphogen turns year-long deficits into first profitable year following Servier acquisition
Symphogen, which was acquired by French Servier two years ago, has succeeded in ending the financial year 2020/2021 with a double-digit million-dollar net result, despite a string of deficits in recent years.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Biotech firm Symphogen, which French pharmaceutical company Servier bought back in 2020, can now finally present financial results in the black, following years of deficits.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings beats records in 2020 and earns DKK 29bn
For subscribers
.jpg&w=384&q=75)
